Enzalutamide

Also known as: MDV3100, MDV-3100, MDV 3100, Xtandi, 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, Enzalutamida, Enzalutamidum, UNII-93T0T9GKNU, N-methyl-4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-2-fluorobenzamide

Enzalutamide (CAS 915087-33-1) is a compound in the Organic Bases category listed in the Jingsj chemical database. It has the molecular formula C21H16F4N4O2S and a molecular weight of 464.436 g/mol. Key property: a density of 1.5±0.1 g/cm3. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 915087-33-1
Jingsj CID: J-1956241-5
Molecular Formula: C₂₁H₁₆F₄N₄O₂S
Molecular Weight: 464.436 g/mol
Category: Organic Bases
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Density	1.5±0.1 g/cm3
Exact Mass	464.093018
PSA	108.53000
LogP	2.13
Refractive Index	1.630

Activity & Biological Data

Target	IC50: 36 nM (androgen-receptor, in LNCaP cells)[1]
Additional Information	[1]. Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324 (5928), 787-790. [2]. Scher HI, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010, 375(9724), 1437-1446. [3]. Guerrero J, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013 Sep;73(12):1291-305. [4]. Kim TH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38(11):2076-82.

Target

IC50: 36 nM (androgen-receptor, in LNCaP cells)[1]

Additional Information

[1]. Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324 (5928), 787-790. [2]. Scher HI, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010, 375(9724), 1437-1446. [3]. Guerrero J, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013 Sep;73(12):1291-305. [4]. Kim TH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38(11):2076-82.

Customs & Trade Information

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Frequently Asked Questions

What is the CAS number of Enzalutamide?

The CAS number of Enzalutamide is 915087-33-1.

What are the molecular formula and molecular weight of Enzalutamide?

Enzalutamide has molecular formula C21H16F4N4O2S and molecular weight 464.436 g/mol.

What are the upstream and downstream products of Enzalutamide?

For Enzalutamide, Upstream Products: 4-[(2-Cyanopropan-2-yl)amino]-2-fluoro-N-methylbenzamide, 4-isothiocyanato-2-(trifluoromethyl)benzonitrile, N-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-methylalanine methyl ester.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Enzalutamide (CAS 915087-33-1)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1956241-5 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.